Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01121471 · ClinicalTrials.gov registry record · NA
Supplementation With Conjugated Linoleic Acid (CLA) as Complementary Therapy in the Management of Type 2 Diabetes Mellitus (Women's Diabetes Study)
A NA study, sponsored by Ohio State University.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
NCT01121471 is a NA study that has completed, run by Ohio State University. The registered enrollment target is 55 participants.
The verdict
NCT01121471, a NA study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the role of CLA as a complementary therapy to improve body composition, glucose tolerance, fasting plasma glucose and insulin, and hemoglobinA1c (HbA1c) in subjects with type 2 diabetes mellitus (T2DM).
Interventions
- DIETARY_SUPPLEMENT Conjugated Linoleic Acid (CLA)
- DIETARY_SUPPLEMENT Safflower OIl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01121471
The ClinicalTrials.gov registry entry for NCT01121471 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Conjugated Linoleic Acid (CLA) is the first listed.
NCT01121471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01121471 about?
NCT01121471 is a clinical study titled "Supplementation With Conjugated Linoleic Acid (CLA) as Complementary Therapy in the Management of Type 2 Diabetes Mellitus (Women's Diabetes Study)". The purpose of this study is to determine the role of CLA as a complementary therapy to improve body composition, glucose tolerance, fasting plasma glucose and insulin, and hemoglobinA1c (HbA1c) in subjects with type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT01121471?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2004-12. Estimated completion is 2006-11.
What interventions are being tested in trial NCT01121471?
The interventions under investigation include: Conjugated Linoleic Acid (CLA) (DIETARY_SUPPLEMENT), Safflower OIl (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01121471?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.